Wipfli Financial Advisors LLC Purchases Shares of 1,203 Organon & Co. (NYSE:OGN)

Wipfli Financial Advisors LLC acquired a new position in shares of Organon & Co. (NYSE:OGN – Get Rating) during the third quarter, Holdings Channel reports. The institutional investor acquired 1,203 shares of the company’s stock, valued at approximately $28,000.

Other large investors have also recently made changes to their positions in the company. Investors Asset Management of Georgia Inc. GA ADV acquired a new stake in Organon & Co. during the second quarter valued at $25,000. CoreCap Advisors LLC purchased a new position in shares of Organon & Co. in the 2nd quarter valued at about $27,000. ACG Wealth acquired a new position in Organon & Co. in the 2nd quarter worth about $31,000. Truvestments Capital LLC purchased a new position in Organon & Co. during the second quarter worth approximately $33,000. Finally, Coston McIsaac & Partners acquired a new stake in Organon & Co. in the second quarter valued at approximately $33,000. 75.74% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $31.34 on Friday. Organon & Co. has a 1 year low of $22.88 and a 1 year high of $39.47. The firm has a market capitalization of $7.97 billion, a PE ratio of 7.91 and a beta of 0.71. The business’s 50 day moving average price is $27.63 and its 200-day moving average price is $28.10.

Organon & Co. (NYSE:OGN – Get Rating) last released its earnings results on Thursday, November 3rd. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.20. The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a net margin of 16.07% and a negative return on equity of 114.90%. As a group, analysts expect that Organon & Co. will post 5.11 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 15th. Stockholders of record on Monday, November 14th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 3.57%. The ex-dividend date of this dividend was Thursday, November 10th. Organon & Co.’s dividend payout ratio is currently 28.28%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Bank of America downgraded Organon & Co. from a “neutral” rating to an “underperform” rating and set a $25.00 target price for the company. in a research note on Friday, October 14th. Morgan Stanley decreased their price objective on shares of Organon & Co. from $27.00 to $24.00 and set an “equal weight” rating on the stock in a report on Friday, November 4th.

Organon & Co. Profile

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.